By Malvika Gurung Investing.com -- The domestic market made a higher closing on Friday, snapping two sessions of losses, with the equity benchmark indices ending the week with up to 2%...
- Day's Range
- 408.00 - 414.35
- 52 wk Range
- 319.00 - 486.85
- Prev. Close
- Average Vol.(3m)
- 1-Year Change
- Market Cap
- P/E Ratio
- Shares Outstanding
- Dividend (Yield)
- 2.5 (0.6%)
- Next Earnings Date
- Feb 02, 2023
By Malvika Gurung Investing.com -- The flagship company of Adani (NS:APSE) Group, Adani Enterprises (NS:ADEL) will make its way into one of the most-tracked benchmark equity indices...
By Malvika Gurung Investing.com -- The flagship company of the world’s third richest man Gautam Adani, Adani Enterprises (NS:ADEL) will make its way into one of the most-tracked benchmark...
By Malvika Gurung Investing.com -- HDFC (NS:HDFC): The mortgage lender has raised its benchmark lending rate by 25 basis points, coming into effect from Aug 9, 2022. This is the sixth rate...
By Malvika Gurung Investing.com -- Sun Pharmaceuticals (NS:SUN): The drugmaker subsidiary Taro Pharmaceuticals USA has acquired the subsidiary companies of the Swiss pharma company Galderma,...
By Malvika Gurung Investing.com -- HDFC: The mortgage lender reported a standalone net profit of Rs 3,260.7 crore, up 1.4% YoY, while its total revenue from operations climbed to Rs 11,783.6...
By Malvika Gurung Investing.com -- Indian Railway Catering And Tourism Corp (NS:INIR): The Railways ministry has lifted its decision to do away with all the existing contracts it has of...
By Malvika Gurung Investing.com -- The Ahmedabad-based pharmaceutical company Zydus Cadila announced on Monday that the Union Government has placed an order of 1 crore doses of ZyCoV-D, the...
By Malvika Gurung Investing.com -- Companies including Mahindra & Mahindra (NS:MAHM), Bosch (NS:BOSH), Power Grid (NS:PGRD) Corporation of India, Bharat Heavy Electricals (NS:BHEL),...
By Aditya Raghunath Investing.com -- Domestic institutional investors (DIIs) were heavy buyers of Indian equities in July. They net bought stocks worth Rs 18,393.92 crore in the month. What...
By Aditya Raghunath Investing.com -- Pharma company Lupin Ltd (NS:LUPN) reported its numbers for Q1 FY22. Net profit came in at Rs 542.46 crore compared to Rs 106.9 crore in Q1 FY21....
By Aditya Raghunath Investing.com -- Mutual fund trades are a strong indicator of the potential of a stock. SEBI data says that mutual funds bought Rs 5,526 crore worth net equities in...
May 12 (Reuters) - Cadila Healthcare Ltd CADI.NS :* UNIT ZYDUS ANIMAL HEALTH & INVESTMENT ENTERED INTO BUSINESS TRANSFER AGREEMENT* AGREEMENT FOR DISPOSAL OF UNIT'S ANIMAL HEALTHCARE...
By Amit DaveAHMEDABAD, India, May 11 (Reuters) - Doctors in India are warning against the practice of using cow dung in the belief it will ward off COVID-19, saying there is no scientific...
By Aditya Raghunath Investing.com -- Remdesivir is an anti-viral drug used to treat COVID-19. It is one of the most sought-after during the second wave of the pandemic in India. It has been...
(Adds details)By Sumit KhannaAHMEDABAD, India, April 23 (Reuters) - India's Cadila Healthcare CADI.NS has started producing its potential COVID-19 vaccine for which it will seek emergency...
By Sumit KhannaAHMEDABAD, India, April 23 (Reuters) - India's Cadila Healthcare CADI.NS has started producing its potential COVID-19 vaccine for which it will seek emergency use...
By Soumyajit SahaBENGALURU, April 23 (Reuters) - Indian shares ended lower on Friday to record weekly losses, as an unrelenting surge in COVID-19 cases and deaths deepened fears of further...
BENGALURU, April 23 (Reuters) - India's Cadila Healthcare Ltd CADI.NS received approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19, the drugmaker said on...
April 23 (Reuters) - Cadila Healthcare Ltd CADI.NS :* RECEIVES FINAL APPROVAL FROM USFDA FOR PROPAFENONE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES...
By Aditya Raghunath Investing.com -- Nifty rose 1.36% and the BSE Sensex rose 1.38% one day before a mid-week holiday as markets’ hopes soared on new vaccine approvals. The government...
* India reports 152,879 new infections, total at 13.35 mln* Deaths rise by 839 to total of 169,275 (Adds details)By Devjyot Ghoshal and Krishna N. DasNEW DELHI, April 11 (Reuters) - India on...
BENGALURU, April 9 (Reuters) - Indian shares closed lower on Friday, pressured by modest declines in index heavyweights Reliance Industries and ICICI Bank, while Hindustan Unilever...
(Recasts with J&J response)By Anuron Kumar MitraBENGALURU, April 9 (Reuters) - Johnson & Johnson (NYSE:JNJ) JNJ.N is in talks with India's government to begin a clinical trial of its...
(Adds details, background)BENGALURU, April 5 (Reuters) - India's Cadila Healthcare Ltd CADI.NS has sought approval from local regulators to use a Hepatitis C drug as a treatment for...
BENGALURU, April 5 (Reuters) - Indian drugmaker Cadila Healthcare Ltd CADI.NS said on Monday it would seek local regulatory approval to treat COVID-19 patients with an already approved...
March 25 (Reuters) - Cadila Healthcare Ltd CADI.NS :* SUBSCRIBED TO PARTNERSHIP INTEREST IN ABCD TECHNOLOGIES* DEAL FOR 400 MILLION RUPEES...
March 25 (Reuters) - Cadila Healthcare Ltd CADI.NS :* RECEIVES TENTATIVE APPROVAL FROM USFDA FOR EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS* DRUG WILL BE MADE AT FORMULATION...
March 24 (Reuters) - Cadila Healthcare Ltd CADI.NS :* CADILA HEALTHCARE LTD - REMDESIVIR NOW PRICED AT 899 RUPEES* CADILA HEALTHCARE LTD - EARLIER PRICE OF CO'S REMDESIVIR WAS 2,800 RUPEES...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.